Curis is a leading brand dedicated to developing groundbreaking therapeutics that enhance the lives of cancer patients. With a focus on innovation and differentiation, Curis aims to revolutionize cancer treatment. Their product pipeline includes a range of cutting-edge therapies targeting various stages and types of cancer.

Emavusertib (CA-4948) is a promising candidate that specifically targets hematologic malignancies and other cancers. Fimepinostat and CA-170 have shown great potential in treating MYC-altered cancers and VISTA/PDL1-expressing cancers, respectively. Additionally, Curis has developed Erivedge, an approved drug for the treatment of Hedgehog Basal Cell Carcinoma.

Curis actively engages in clinical studies to gather evidence of its therapeutics' effectiveness, ensuring patient safety and optimizing dosages. The brand collaborates with esteemed scientific and research partners to stay at the forefront of cancer research. Moreover, Curis is driven by a strong commitment to transparency, as demonstrated by their comprehensive corporate governance and financial information available to investors.

Join Curis in their mission to redefine cancer treatment and improve the lives of cancer patients worldwide. Learn more about their innovative therapies and career opportunities on their website